Have a feature idea you'd love to see implemented?
Let us know!
TARS Tarsus Pharmaceuticals Inc
Price (delayed)
$46.4
Market cap
$1.77B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.77
Enterprise value
$1.67B
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline
Highlights
Tarsus Pharmaceuticals's gross profit has soared by 56% from the previous quarter
The company's revenue has surged by 55% QoQ
The company's net income fell by 25% YoY but it rose by 10% QoQ
The company's equity rose by 11% YoY but it fell by 6% QoQ
Tarsus Pharmaceuticals's debt has surged by 141% YoY
The company's quick ratio has shrunk by 52% YoY and by 23% QoQ
Key stats
What are the main financial stats of TARS
Market
Valuations
Earnings
Shares outstanding
38.23M
Market cap
$1.77B
Enterprise value
$1.67B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.43
Price to sales (P/S)
13.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.88
Revenue
$129.62M
EBIT
-$127.82M
EBITDA
-$126.08M
Free cash flow
-$101.68M
Per share
Balance sheet
Liquidity
EPS
-$3.77
Free cash flow per share
-$2.65
Book value per share
$6.24
Revenue per share
$3.38
TBVPS
$9.58
Total assets
$376.3M
Total liabilities
$138.82M
Debt
$71.71M
Equity
$237.48M
Working capital
$291.25M
Debt to equity
0.3
Current ratio
5.42
Quick ratio
5.27
Net debt/EBITDA
0.83
Margins
Efficiency
Dividend
EBITDA margin
-97.3%
Gross margin
93%
Net margin
-103.6%
Operating margin
-108.5%
Return on assets
-39.3%
Return on equity
-55.9%
Return on invested capital
-88.4%
Return on capital employed
-41.2%
Return on sales
-98.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARS stock price
How has the Tarsus Pharmaceuticals stock price performed over time
Intraday
-0.39%
1 week
-0.54%
1 month
27.3%
1 year
164.09%
YTD
129.14%
QTD
41.08%
Financial performance
How have Tarsus Pharmaceuticals's revenue and profit performed over time
Revenue
$129.62M
Gross profit
$120.51M
Operating income
-$140.6M
Net income
-$134.34M
Gross margin
93%
Net margin
-103.6%
Tarsus Pharmaceuticals's net margin has surged by 86% YoY and by 42% QoQ
Tarsus Pharmaceuticals's operating margin has soared by 86% YoY and by 42% from the previous quarter
Tarsus Pharmaceuticals's gross profit has soared by 56% from the previous quarter
The company's revenue has surged by 55% QoQ
Growth
What is Tarsus Pharmaceuticals's growth rate over time
Valuation
What is Tarsus Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.43
P/S
13.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.88
The company's EPS rose by 15% QoQ
TARS's P/B is 140% above its 5-year quarterly average of 3.1 and 73% above its last 4 quarters average of 4.3
The company's equity rose by 11% YoY but it fell by 6% QoQ
The company's revenue has surged by 55% QoQ
The P/S is 36% lower than the last 4 quarters average of 21.6
Efficiency
How efficient is Tarsus Pharmaceuticals business performance
The company's return on sales has surged by 86% YoY and by 43% QoQ
TARS's return on invested capital is up by 35% since the previous quarter and by 4.2% year-on-year
The ROA has grown by 18% YoY and by 17% from the previous quarter
TARS's ROE is up by 13% from the previous quarter and by 5% YoY
Dividends
What is TARS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARS.
Financial health
How did Tarsus Pharmaceuticals financials performed over time
TARS's total assets is 171% greater than its total liabilities
Tarsus Pharmaceuticals's total liabilities has soared by 154% YoY and by 11% from the previous quarter
The company's quick ratio has shrunk by 52% YoY and by 23% QoQ
Tarsus Pharmaceuticals's debt is 70% lower than its equity
Tarsus Pharmaceuticals's debt has surged by 141% YoY
The debt to equity has soared by 114% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.